ExoVasc® PEARS

18 Year old undertakes PEARS procedure

A further patient received the ExoVasc® support in late September. For Professor John Pepper this successful operation on an 18-year old patient adds new data to the clinical trial. Results on the 12 – 48 month follow-up of the first group of patients in the trial are currently being analysed in preparation for the publication of a scientific paper.

Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support

The 11 Beaches Walk raises money for research into cardiovascular disease

Interested in our patient experiences?

We develop medical devices that manage aortic dilation and minimise the risk of aortic dissection.

quick links

statements & policies

Our contact details

The staff of Exstent Limited are not medically qualified and are thus not able to provide clinical advice or answer questions of a clinical nature. We may direct your attention to publications in peer-reviewed journals that provide clinical information or provide information based upon personal experience. However, for any questions of a clinical nature patients are recommended to consult a qualified clinician.